Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibrinogen - Octapharma

Next Previous
Drug Profile

Fibrinogen - Octapharma

Alternative Names: Factor I concentrate-Octapharma; Fibrinogen (Human) Lyophilised Powder for Reconstitution; FIBRYGA; Fibryga; Fibryna; Human fibrinogen concentrate; Octafibrin

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Octapharma
  • Developer Octapharma; University Health Network of Toronto
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Afibrinogenaemia

Most Recent Events

  • 28 May 2025 Launched for Afibrinogenaemia in Denmark (IV)
  • 12 May 2025 Launched for Afibrinogenaemia in Sweden (IV)
  • 02 May 2025 Launched for Afibrinogenaemia in Ukraine (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top